Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 40
- Registration Number
- NCT06555471
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06547385
- Locations
- 🇯🇵
Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo, Japan
🇯🇵Osaka Medical and Pharmaceutical University Hospital, Takatsuki-shi, Osaka, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 550
- Registration Number
- NCT06532006
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Adaptive Therapy With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 35
- Registration Number
- NCT06525766
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 350
- Registration Number
- NCT06519370
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT06507371
- Locations
- 🇨🇳
Sir Run Run Shao hospital, Hanzhou, Zhejiang, China
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Target Recruit Count
- 30
- Registration Number
- NCT06504901
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Target Recruit Count
- 23
- Registration Number
- NCT06504875
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 130
- Registration Number
- NCT06493760
- Locations
- 🇨🇳
Liu Tianshu, Shanghai, Shanghai, China
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT06494995
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.